CENTER FOR NEUROLOGICAL DISORDERS, S.C.
Clinical Research
Clinical research continues to transform the landscape of treatment for neurological conditions. Thanks to carefully designed and rigorously conducted trials, patients today have access to therapies that are safer and more effective than ever before—with many promising new options on the horizon.
​
Our dedicated research division, BCN Research, leads multiple clinical trials evaluating both FDA-approved therapies and innovative treatments not yet available to the public. In addition, we conduct independent studies that address critical questions about the diseases and conditions we treat, generating insights that can directly benefit our patients.
1
argenx PASS (Post-Authorization Safety Study) of efgartigimod alfa (VYVGART or VYVGART HYTRULO) in Generalized Myasthenia Gravis
This is an observational study (not testing a new treatment vs placebo), designed to monitor how people with generalized myasthenia gravis (gMG) fare when prescribed efgartigimod (brand name: VYVGART or VYVGART HYTRULO) under real-world conditions. It compares outcomes in patients who receive efgartigimod at the start or soon after enrollment with those who do not receive it. The goal is to collect safety data and understand its use in routine care. (NCT06298565)
2
APPRAISE - A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 75 Years With gMG.
This is a phase III clinical trial evaluating iptacopan, an oral drug, in adults with generalized myasthenia gravis (gMG) who are positive for acetylcholine receptor antibodies. Participants are randomly assigned to receive either iptacopan or a placebo for six months while continuing their usual care. After this period, everyone has the option to enter an open-label extension phase where they receive iptacopan for up to two years. The study aims to find out whether iptacopan can safely and effectively reduce the symptoms of gMG, and whether it continues to help over the long term. (NCT06517758)
3
RELIEVE - A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis
This is a phase III trial, testing remibrutinib, a new oral medication for adults with generalized myasthenia gravis. Participants receive either remibrutinib or a placebo in a double-blind fashion for six months while continuing their standard treatments. After this phase, all participants can enter a longer open-label extension period to receive remibrutinib for up to five years. The goal is to determine whether remibrutinib improves gMG symptoms and remains safe and tolerable during extended use. (NCT06744920)
4
RemeMG - A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis
RemeMG is a phase III trial studying telitacicept, an injectable biologic drug, in people with generalized myasthenia gravis who test positive for certain autoantibodies. The first 24 weeks of the study are double-blind and placebo-controlled, meaning neither the participants nor the researchers know who is receiving the drug. After that, everyone can receive telitacicept in an open-label extension phase. The main aim is to see whether telitacicept can effectively reduce gMG symptoms and to monitor for any side effects over time. (NCT06456580)
Get in Touch
This is a Paragraph. Click on "Edit Text" or double click on the text box to start editing the content.